Valley Brook Capital Group
ABBV icon

Valley Brook Capital Group’s AbbVie ABBV Stock Holding History

Valley Brook Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.04M Sell
23,099
-47
-0.2% -$12K 3.4% 6
2026
Q2 		$5.82M Buy
23,146
+183
+0.8% +$39.4K 3.3% 7
2026
Q1 		$4.99M Sell
22,963
-103
-0.4% -$22.8K 3.35% 6
2025
Q4 		$5.27M Buy
23,066
+146
+0.6% +$33.3K 3.49% 6
2025
Q3 		$5.31M Buy
22,920
+128
+0.6% +$26.1K 3.57% 6
2025
Q2 		$4.23M Sell
22,792
-125
-0.5% -$23.2K 3.17% 7
2025
Q1 		$4.8M Buy
22,917
+218
+1% +$42.4K 3.77% 3
2024
Q4 		$4.03M Sell
22,699
-88
-0.4% -$16.2K 3.01% 6
2024
Q3 		$4.5M Sell
22,787
-58
-0.3% -$10.8K 3.23% 4
2024
Q2 		$3.92M Buy
22,845
+96
+0.4% +$15.9K 3.05% 5
2024
Q1 		$4.14M Sell
22,749
-96
-0.4% -$16.5K 3.31% 4
2023
Q4 		$3.54M Buy
22,845
+128
+0.6% +$18.7K 3.08% 4
2023
Q3 		$3.39M Buy
22,717
+468
+2% +$68.7K 3.35% 4
2023
Q2 		$3M Sell
22,249
-891
-4% -$131K 2.77% 5
2023
Q1 		$3.69M Sell
23,140
-239
-1% -$36.5K 3.4% 4
2022
Q4 		$3.78M Buy
23,379
+357
+2% +$54.7K 3.62% 4
2022
Q3 		$3.09M Buy
23,022
+107
+0.5% +$15.4K 3.37% 5
2022
Q2 		$3.51M Sell
22,915
-400
-2% -$61.1K 3.62% 5
2022
Q1 		$3.78M Buy
23,315
+1,206
+5% +$175K 3.26% 4
2021
Q4 		$2.99M Buy
22,109
+208
+0.9% +$24.6K 2.58% 6
2021
Q3 		$2.36M Sell
21,901
-1,123
-5% -$128K 2.34% 9
2021
Q2 		$2.59M Buy
23,024
+627
+3% +$70.6K 2.47% 8
2021
Q1 		$2.42M Buy
22,397
+610
+3% +$65.2K 2.19% 8
2020
Q4 		$2.33M Buy
+21,787
New +$2.09M 2.31% 6

Other funds holding ABBV

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Valley Brook Capital Group's ABBV Position: Q3 2026 in Review

Valley Brook Capital Group reduced its AbbVie (ABBV) stake by 0.2% in Q3 2026, selling an estimated $12K and leaving 23,099 shares worth $6.04M. The position accounts for 3.4% of the portfolio, ranked #6.

Valley Brook Capital Group first reported a position in ABBV in Q4 2020 and has held it in 24 quarters since. 3,416 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Valley Brook Capital Group held 23,099 shares of AbbVie worth $6.04M as of Q3 2026.
  • Valley Brook Capital Group sold 47 AbbVie shares in Q3 2026, an estimated $12K.
  • AbbVie made up 3.4% of Valley Brook Capital Group's portfolio in Q3 2026, its #6 holding.
  • Valley Brook Capital Group first reported a position in AbbVie in Q4 2020 and has held it in 24 quarters since.
  • 3,416 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Valley Brook Capital Group's 13F filing for Q3 2026, filed 26 Oct 2026.